- SARS-CoV-2 Inhibition, Host Selection and Next-Move Prediction Through High-Performance Computing, funded by the Instituto de Salud Carlos III in the framework of the call “Expressions of interest for the financing of research projects on SARS- Cov-2 and Covid-19 disease” (Dr.
Modesto Orozco).
- 2019 Rapid interaction profiling of drug-nCoV for deep-network-based repurpose learning, funded by H2020 (call H2020-SC1-PHE-CORONAVIRUS-2020). In collaboration with the Helmholtz Zentrum München (coordinator) and INSERM, this action lasts for 3 years (Dr. Patrick Aloy).
- Preclinical development of innovative mRNA / MVA vaccines against SARS-CoV2 (COVARNA) involved IRB Barcelona researcher Núria López-Bigas. It is a consortium led by Dr. Felipe Garcia of IDIBAPS, with the participation of the partners UB, UPF, CNB-CSIC, Universidad Santiago de Compostela and Université Libre de Bruxelles. The project obtained two official sources of funding: the DGRIS from the Department of Health and the ISCIII.
- ACE-2-derived peptide super-binders with enhanced efficacy for inhibition of SARS-COV-2 infection. Drs. Antonio Zorzano and Manuel Palacín obtained funding in the Fondo-Supera Covid CRUE-Santander call in a project coordinated by the Public University of Navarra.
- Dr. Patrick Aloy’s lab started a collaboration with Amazon Search Science and AI group to develop a computer tool using artificial intelligence that will accelerate the search for drugs against COVID-19.
